Baseline Characteristics of LHON Subjects in the RESCUE and REVERSE Phase III Gene Therapy Trials

Update Item Information
Identifier 20180306_nanos_posters_161
Title Baseline Characteristics of LHON Subjects in the RESCUE and REVERSE Phase III Gene Therapy Trials
Creator Mark Moster, Catherine Vignal, Nancy Newman, Alfredo Sadun, Patrick Yu-Wai-Man, Valerio Carelli, Thomas Klopstock, Adam Debusk, Robert Sergott, Molly Scannel Bryan, Jose-Alain Sahel, Barrett Katz, Scott Uretsky
Subject Genetic Disease; Optic Neuropathy
Description RESCUE and REVERSE are Phase‑ III, randomized, multicenter, double‑masked, sham‑ controlled trials of rAAV2/2-ND4, an intravitreally injected gene therapy for treatment of ND4‑ LHON. RESCUE subjects had vision loss for ≤6 months and REVERSE subjects from >6 months up to 1 year.
Date 2018-03
Language eng
Format application/pdf
Source 2018 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2018: Poster Presentations
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2018. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s65q8w8p
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Contributor Primary Mark Moster
Contributor Secondary Catherine Vignal, Nancy Newman, Alfredo Sadun, Patrick Yu-Wai-Man, Valerio Carelli, Thomas Klopstock, Adam Debusk, Robert Sergott, Molly Scannel Bryan, Jose-Alain Sahel, Barrett Katz, Scott Uretsky
Setname ehsl_novel_nam
ID 1309581
Reference URL https://collections.lib.utah.edu/ark:/87278/s65q8w8p
Back to Search Results